Crijns F R, Struijker Boudier H A, Wolffenbuttel B H
Department of Endocrinology and Metabolism, Cardiovascular Research Institute, University Hospital Maastricht, The Netherlands.
Diabetes. 1998 Jun;47(6):918-23. doi: 10.2337/diabetes.47.6.918.
The effect of 6 weeks' streptozotocin (STZ)-induced (70 mg/kg) diabetes and aminoguanidine (AG) treatment (50 mg/kg s.c. or 250-750 mg/l given in drinking water) on arteriolar reactivity to vasoactive substances was investigated in conscious rats. Studies were performed in untreated control rats (n = 13), STZ-induced diabetic rats (n = 11), AG-treated control rats (n = 12), and AG-treated diabetic rats (n = 12). Rats were provided with a dorsal microcirculatory chamber that allowed intravital microscopy of striated muscle arterioles of varying diameter (A1, large; A2, intermediate; and A3, small arterioles) in conscious animals. The mean arterial pressure (MAP) and arteriolar diameter responses to intravenous infusion of the following drugs were examined: the endothelium-dependent vasodilator acetylcholine (ACh; 3, 10, and 30 microg x kg(-1) x min(-1)), the potassium-channel opener levcromakalim (LC; 30 microg/kg), and the vasoconstrictor agents ANG II (0.1 and 0.3 microg x kg(-1) x min(-1)) and norepinephrine (NE; 0.2, 0.6, and 2.0 microg x kg(-1) x min(-1)). Baseline MAP was lower in both diabetic groups versus the nondiabetic groups (P < 0.05). AG treatment had no influence on baseline MAP. The absolute change in MAP after drug infusion tended to be lower in the diabetic rats than in their nondiabetic littermates. Arteriolar vasodilatory responses to ACh and LC were attenuated in the diabetic animals (1 +/- 7 vs. 19 +/- 7% [P < 0.05] and 7 +/- 3 vs. 34 +/- 8% [P < 0.01] in A2, respectively). AG treatment of diabetic animals did not prevent the development of this disturbance. Vasoconstrictor responses were not influenced by the diabetic state. In the intermediate arterioles of AG-treated control rats, a hyperresponse was observed after ANG II infusion (-10 +/- 2 vs. -2 +/- 2%; P < 0.05) and a hyporesponse was observed after ACh and LC infusion (2 +/- 3 and 15 +/- 6%, respectively; P < 0.05 vs. untreated control rats). These data indicate that 6 weeks of experimental diabetes is associated with a decreased endothelium-dependent and -independent vasodilatation. AG treatment had no beneficial effect on this disturbance.
研究了链脲佐菌素(STZ)诱导(70mg/kg)6周糖尿病及氨基胍(AG)治疗(皮下注射50mg/kg或饮用水中给予250 - 750mg/L)对清醒大鼠小动脉对血管活性物质反应性的影响。实验对象包括未治疗的对照大鼠(n = 13)、STZ诱导的糖尿病大鼠(n = 11)、AG治疗的对照大鼠(n = 12)以及AG治疗的糖尿病大鼠(n = 12)。给大鼠安装背部微循环室,可在清醒动物体内对不同直径的横纹肌小动脉(A1,大;A2,中;A3,小动脉)进行活体显微镜观察。检测了静脉输注以下药物时的平均动脉压(MAP)和小动脉直径反应:内皮依赖性血管舒张剂乙酰胆碱(ACh;3、10和30μg·kg⁻¹·min⁻¹)、钾通道开放剂利克罗卡利姆(LC;30μg/kg)以及血管收缩剂血管紧张素II(ANG II;0.1和0.3μg·kg⁻¹·min⁻¹)和去甲肾上腺素(NE;0.2、0.6和2.0μg·kg⁻¹·min⁻¹)。与非糖尿病组相比,两个糖尿病组的基线MAP均较低(P < 0.05)。AG治疗对基线MAP无影响。糖尿病大鼠输注药物后MAP的绝对变化趋势低于其非糖尿病同窝大鼠。糖尿病动物对ACh和LC的小动脉舒张反应减弱(A2中分别为1 ± 7%对19 ± 7% [P < 0.05]和7 ± 3%对34 ± 8% [P < 0.01])。对糖尿病动物进行AG治疗并不能阻止这种紊乱情况的发生。血管收缩反应不受糖尿病状态影响。在AG治疗的对照大鼠的中等小动脉中,输注ANG II后观察到高反应(-10 ± 2%对-2 ± 2%;P < 0.05),输注ACh和LC后观察到低反应(分别为2 ± 3%和15 ± 6%;与未治疗的对照大鼠相比P < 0.05)。这些数据表明,6周的实验性糖尿病与内皮依赖性和非依赖性血管舒张功能降低有关。AG治疗对这种紊乱情况无有益作用。